Trial Profile
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Jun 2022
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Warfarin
- Indications Stroke; Transient ischaemic attacks
- Focus Therapeutic Use
- Acronyms AREST
- 26 Apr 2022 Results assessing effects of initiation of anti-seizure medications in Atrial Fibrillation-related stroke presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 04 Apr 2022 Results assessing quality of life and anticoagulation in atrial fibrillation Patients presented at the 71st Annual Scientific Session of the American College of Cardiology
- 11 Feb 2022 Results of sub study, finding whether there is also an association between AF burden and recurrent cerebrovascular events in anticoagulated AF patients after their initial acute ischemic stroke (AIS) or transient ischemic attacks (TIA), presented at the International Stroke Conference 2022